Expert digest
Credentialed experts on podcasts, in newsletters and at conferences, paraphrased with verbatim quotes, tier-coded for citation rigour.
What experts said about BPC-157 in Q2 2026
A digest of on-record expert commentary on BPC-157 from Q2 2026, with credentials, conflicts of interest, and the evidence gaps each expert flagged.
What experts said about CJC-1295 in Q2 2026
On-record expert commentary on CJC-1295 from Q2 2026: the evidence gap, cancer-risk concerns, regulatory shifts, and the upcoming PCAC review.
Ipamorelin: what experts said, Q2 2026
On-record expert commentary on ipamorelin from Q2 2026, with credentials, conflicts of interest, and the FDA regulatory picture.
What experts said about PT-141 in Q2 2026
On-record expert commentary on PT-141 from Q2 2026: arguments for male trials, a Harvard meta-analysis, and Palatin's obesity pivot.
What Penn Medicine's 'food noise' case study actually showed
Casey Halpern's Nature Medicine case study recorded nucleus-accumbens activity in a single patient on tirzepatide. Activity was suppressed early, then returned at 5 months alongside renewed cravings.